• Home
  • Antibody-drug Conjugates Research
  • Antibody-drug Conjugates Manufacturing
  • News
Creative Biolabs ADC Blog

Menu

Skip to content
  • Home
  • Antibody-drug Conjugates Research
  • Antibody-drug Conjugates Manufacturing
  • News

Category Archives: Review

18Mar/24

Several Ways to Sort Out Sulfhydryl-Conjugated ADCs

March 18, 2024ReviewADCs, Sulfhydryl-Conjugatedbioadc

The popularity of sulfhydryl groups in ADC preparation can be traced back to three factors: (a) thiols are the most nucleophilic amino acid side-chain functional group (much more nucleophilic than amines); (b)Read More…

24Feb/24

A Review of Bispecific ADC

February 24, 2024ReviewBispecific ADC, conjugation strategy, MEDI4276, ZW49bioadc

Antibody-drug conjugates (ADCs) comprise an antibody, a linker, and a cytotoxic active payload. Compared to traditional chemotherapy, ADCs that target tumors are expected to mitigate systemic toxic effects, provide a wider therapeuticRead More…

22Dec/23

Key Points of ADC Optimization Strategy

December 22, 2023ReviewADC linker, ADC Optimization, antibody-drug conjugatebioadc

Antigen Target Selection A major challenge in developing antibody-drug conjugates (ADCs) for cancer lies in the identification and validation of sufficient antigen targets for the monoclonal antibody component. Several factors need toRead More…

30Nov/23

New Paradigm—Small Nucleic Acid Antibody Conjugates

November 30, 2023ReviewAntibody-oligonucleotide Conjugatesbioadc

Nucleic acid drugs are a frontier field in the development of biomedicine, and the targeted delivery system of nucleic acid drugs is both a difficult and important point. At present, small nucleicRead More…

25Oct/23

ADC Drugs on the Market: An Overview

October 25, 2023ReviewADC Drugs, antibody-drug conjugatebioadc

Antibody-drug conjugates, often referred to as ADCs, are a type of dual-targeted therapeutic. They consist of three key components: an antibody, a payload, and a linker. The antibody determines the target disease,Read More…

06Oct/23

The Development Trends of the Next Generation of ADC Drugs

October 6, 2023ReviewADC Drugs Development Trendsbioadc

The development trends of the next generation of ADC (antibody-drug conjugate) drugs can be observed to show improved specificity and cytotoxicity compared to earlier generations, driven by technological advancements. However, it’s importantRead More…

06Oct/23

Four Classic Fixed-point Coupling Techniques for ADC

October 6, 2023Reviewsite-specific conjugationbioadc

ADC (antibody-drug conjugate) has emerged as a promising class of anti-cancer drugs, with over a dozen ADC drugs currently approved for the treatment of various types of cancer patients. Traditional ADCs utilizeRead More…

01Sep/23

A General Review of ADC Adverse Reactions Published

September 1, 2023ReviewADC design, ADC Stability, antibody-drug conjugatebioadc

In recent years, the development of antibody-drug conjugate (ADC) therapies has flourished, leading to significant advancements in treating solid tumors. The FDA has approved six solid tumor ADCs so far—Sacituzumab govitecan (SG),Read More…

31Jul/23

How to Develop ADC in the Future?

July 31, 2023ReviewADCs Developmentbioadc

ADC has established a solid position in the oncology pharmacopoeia. Over 1,500 clinical trials of ADCs are listed on clinicaltrials.gov, and an increasing number of drugs are entering clinical trials. It canRead More…

31Jul/23

How to Break the Limitations of ADCs?

July 31, 2023ReviewADCs Research, ADCs Reviewbioadc

Like most drugs, the development interruption of ADCs is typically due to a lack of efficacy, safety issues, commercial considerations, or a combination of these factors. Since 2000, among the 97 ADCsRead More…

Posts navigation

  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next »

Categories

Recent Posts

  • Harnessing Synergy: How Antibody-Drug Conjugates and Immunotherapy Are Reshaping Breast Cancer Treatment
  • Fragment-Drug Conjugates: Innovations in ADC Development
  • Antibody-Oligonucleotide Conjugates (AOCs): Merging Precision and Therapeutic Potential
  • Bispecific ADCs: Redefining Precision in Targeted Cancer Therapy
  • The Future of Cancer Care: What Antibody-Drug Conjugates Will Bring and What We Have Already Done

Archives

Contact Us

USA - UK

Copyright © Creative Biolabs ADC Blog
Powered by WordPress , Theme i-max by TemplatesNext.
MENU
  • Home
  • Antibody-drug Conjugates Research
  • Antibody-drug Conjugates Manufacturing
  • News